Richard Rosenquist Brandell has been named Pharmaceutical Profile of the Year 2025 for his dedicated work in building a national infrastructure for precision medicine. The award is presented by Läkemedelsmarknaden in collaboration with Dagens Medicin and Dagens Industri.
Richard Rosenquist Brandell is a senior consultant in clinical genetics at Karolinska University Hospital and Professor at the Department of Molecular Medicine and Surgery, Karolinska Institutet. In addition, he is the director of Genomic Medicine Sweden (GMS).
The Pharmaceutical Profile of the Year award recognizes individuals who build bridges between healthcare, industry, research, and patients, and who involve patients in development efforts within healthcare.
Motivation
"As director of Genomic Medicine Sweden (GMS), Richard Rosenquist Brandell has built a team that, since 2018, has worked purposefully to establish a national infrastructure for improved diagnostics, personalized treatment choices, and research in the field of precision medicine. This development is carried out in collaboration with healthcare, authorities, patient organizations, industry, and academia."
"The strength of GMS lies in the very close collaboration between all stakeholders, which has made it possible for us to offer precision diagnostics nationwide. I feel deeply honored as a clinical geneticist to receive this award, it truly came as a surprise," says Richard Rosenquist Brandell, director of GMS.
The award was presented on December 4, 2025.
